Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buntanetap in early Parkinson's disease
2022-001542-38Phase 3Completed
- Sponsor
- Annovis Bio, Inc.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buntanetap in Parkinson's disease (PD) (3 arms), sponsored by Annovis Bio, Inc. Primary endpoint: Change from baseline to Month 6 in the sum of MDS-UPDRS Part II+III. Started Aug 2022; status: completed.
02
Drugs
buntanetap
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2022-001542-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001542-38.